首页 | 本学科首页   官方微博 | 高级检索  
     

消栓通络胶囊联合尤瑞克林治疗急性脑梗死的临床研究
引用本文:刘惠钦,范月辉,孟丽,李伟峰. 消栓通络胶囊联合尤瑞克林治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2022, 37(12): 2760-2764
作者姓名:刘惠钦  范月辉  孟丽  李伟峰
作者单位:石家庄市人民医院 神经内科, 河北 石家庄 050000
基金项目:石家庄市科学技术研究与发展计划项目(181461043)
摘    要:目的 观察消栓通络胶囊联合尤瑞克林治疗急性脑梗死的临床疗效。方法 选择2019年5月—2022年5月在石家庄市人民医院诊治的106例急性脑梗死患者,按照随机数字表法分对照组(53例)和治疗组(53例)。对照组静脉滴注注射用尤瑞克林,0.15 PNA单位/次,溶于生理盐水100 mL,1次/d。在对照组的基础上,治疗组口服消栓通络胶囊,6粒/次,3次/d。两组用药14 d。观察两组患者临床疗效,比较治疗前后两组患者症状改善时间,NIHSS评分,Barthel指数,血清细胞间黏附分子-1(ICAM-1)、血管细胞间黏附分子-1(VCAM-1)、白细胞介素-8(IL-8)和血管内皮生长因子(VEGF)水平,及不良反应。结果 治疗后,治疗组总有效率(98.11%)明显高于对照组(81.13%,P<0.05)。治疗后,治疗组症状改善时间均明显早于对照组(P<0.05)。治疗后,两组NIHSS评分明显降低,而Barthel指数评分明显升高(P<0.05),且治疗组评分明显好于对照组(P<0.05)。治疗后,两组血清IL-8、ICAM-1、VCAM-1水平明显降低,而VEGF...

关 键 词:消栓通络胶囊  注射用尤瑞克林  急性脑梗死  细胞间黏附分子-1  血管细胞间黏附分子-1  血管内皮生长因子
收稿时间:2022-05-06

Clinical study on Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke
LIU Hui-qin,FAN Yue-hui,MENG Li,LI Wei-feng. Clinical study on Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke[J]. Drugs & Clinic, 2022, 37(12): 2760-2764
Authors:LIU Hui-qin  FAN Yue-hui  MENG Li  LI Wei-feng
Affiliation:Department of Neurology, Shijiazhuang People''s Hospital, Shijiazhuang 050000, China
Abstract:Objective To investigate the effect of Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke. Methods Patients (106 cases) with acute ischemic stroke in Shijiazhuang People''s Hospital from May 2019 to May 2022 were divided into control (53 cases) and treatment (53 cases) group according to the random number table method. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA/time dissolved in normal saline 100 mL, once daily. Patients in the treatment group po administered with Xiaoshuan Tongluo Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, the improvement time of symptom, NIHSS score, Barthel index, the levels of serological indexes IL-8, ICAM-1, VCAM-1, and VEGF, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (98.11%) was significantly higher than that of the control group (81.13%, P<0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P<0.05). After treatment, the NIHSS score in two groups were significantly decreased, while the Barthel index score were significantly increased (P<0.05), and the scores in the treatment group were significantly better than that of the control group (P<0.05). After treatment, the serum levels of IL-8, ICAM-1, and VCAM-1 in two groups were significantly decreased, while the level of VEGF were significantly increased, and the level of serum factors in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion The effect of Xiaoshuan Tongluo Capsules combined with uriculin in treatment of acute ischemic stroke is definite, and can effectively improve the blood supply and cerebral nerve function in the ischemic area of the patients.
Keywords:Xiaoshuan Tongluo Capsules  Urinary Kallidinogenase for injection  acute ischemic stroke  ICAM-1  VCAM-1  VEGF
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号